March 8, 2021
Abbott announced today that it has updated NeuroSphere, its app-driven neuromodulation therapy platform, with remote programming capabilities that will allow patients to speak with and receive adjustments from their provider via a cellular or WiFi connection.
The NeuroSphere Virtual Clinic was recently approved by the FDA and is now available within the Abbott patient controller app for use with...
July 24, 2020
Abbott has received FDA approval for a neuromodulation system-controller app that runs on iOS devices, the company announced Thursday.
Compatible with Abbott's broader NeuroSphere Digital Care platform, the Patient Controller app replaces the separate device patients use to adjust the company's neuromodulation products. These include the Infinity DBS System for Parkinson's disease or essential...
January 27, 2020
Abbott’s Infinity Deep Brain Stimulation (DBS) system has received an expanded clearance from the FDA that now permits the targeted stimulation of a new area of the brain associated with Parkinson’s disease symptoms.
By now targeting the internal globus pallidus alongside the subthalamic nucleus and ventral intermediate nucleus, the company says that its system “is now the only directional DBS...